The Prescient Therapeutics Ltd (ASX: PTX) share price is soaring today, despite the company not releasing any news.
The last time we heard price-sensitive news from the biotechnology company was on 5 July.
Right now, the Prescient Therapeutics share price is 23 cents – 12.2% higher than it was at close of market yesterday.
Prescient Therapeutics focuses on therapies for cancer treatment. Let’s take a closer look at what the company has been up to lately.
The month that’s been for Prescient
Over the last 30 days, 2 major announcements saw the Prescient Therapeutics share price moving dramatically.
The first was on 24 June, when the company released news of its next-generation immunotherapy platform.
Prescient Therapeutics told the market it had incorporated SpyTag into binders for its 3 next-generation CAR-T programs.
The company also received lentiviral vectors that will help produce CAR-T cells expressing SpyCatcher.
Despite the seemingly positive news, the Prescient Therapeutics share price fell 13% that day and another 5% the day after.
Then, on 5 July, the company announced immunogenicity testing had been completed on the company’s OmniCAR therapy.
The components of OmniCAR, which include SpyTag and SpyCatcher, received positive results from in silico immunogenicity testing. The testing substantially de-risked OmniCAR.
In silico tests are those done using computer modelling. In this case, they simulated the body’s response to OmniCAR.
Following the news, the Prescient Therapeutics share price gained 13%.
However, between market close on July 5 and market close yesterday, the company’s share price fell 19%.
Fortunately, today has helped to turn the plunge around.
Prescient Therapeutics share price snapshot
Prescient Therapeutics is going well on the ASX lately.
Its share price is currently 243% higher than it was at the beginning of 2021.
The company has a market capitalisation of around $147 million, with approximately 641 million shares outstanding.
The post The Prescient (ASX: PTX) share price is surging 12%. Here’s why appeared first on The Motley Fool Australia.
Should you invest $1,000 in Prescient Therapeutics right now?
Before you consider Prescient Therapeutics, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Prescient Therapeutics wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of May 24th 2021
More reading
- Why is the Prescient (ASX:PTX) share price down 16% this week?
- The Prescient (ASX:PTX) share price rocketed 10% higher today. Here’s why
- Prescient (ASX:PTX) share price sinks despite positive update
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.
from The Motley Fool Australia https://ift.tt/3BsqGQP
Leave a Reply